News
Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.
The White House has blamed the Biden administration for failing to advance domestic production or fill the reserve.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback